Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement
about
Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapyBenefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodiesDiagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature reviewTherapeutic implications of autoantibodies in rheumatoid arthritisThe effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responsesThe Role of Posttranslational Protein Modifications in Rheumatological Diseases: Focus on Rheumatoid ArthritisA Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis PatientsA new target for autoantibodies in patients with rheumatoid arthritis.Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium.Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy.Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritisAntibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis.The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis.Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritisDiagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritisBaseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow upCross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.Diagnosis and prognosis of early rheumatoid arthritis, with special emphasis on laboratory analysis.Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: a case studyMultiplexing molecular diagnostics and immunoassays using emerging microarray technologies.Adalimumab for rheumatoid arthritis.Higher levels of autoantibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis than in patients with psoriasis vulgarisAntibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis.Autoantibody production in anti-TNF-alpha-treated patients.Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.Cross-linking of IgGs bound on circulating neutrophils leads to an activation of endothelial cells: possible role of rheumatoid factors in rheumatoid arthritis-associated vascular dysfunction.A Contra Capture Protein Array Platform for Studying Post-translationally Modified (PTM) Auto-antigenomes.Different properties of ACPA and IgM-RF derived from a large dataset: further evidence of two distinct autoantibody systems.The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases.Targeted therapies in rheumatoid arthritis: Focus on rituximab.Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis.Autoantibodies to posttranslational modifications in rheumatoid arthritis.Genetic and genomic predictors of anti-TNF response.Clinical parameters and biomarkers for anti-TNF treatment prognosis in rheumatoid arthritis patients.Tumor necrosis factor-α blockade treatment decreased CD154 (CD40-ligand) expression in rheumatoid arthritis.Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.
P2860
Q21195370-40C90A24-030D-4CD1-B13D-DCC60A8C091BQ24627677-D609B5C4-0C08-40C8-A492-A16CA2D917E9Q24675281-197242F6-A226-41E5-A53A-B6FE52BE0E7CQ26744033-8F379634-3B37-403E-88C2-9E3EDC7D0207Q27022645-80A58468-9519-45A1-A083-0270BB870AC8Q28395318-35C3DCE6-118F-4479-AA5A-7CD12060809FQ28551075-906578A7-80F3-4291-8170-4F39EFAB6066Q33300254-EDCB0D6C-4695-49D8-B710-AEA035226037Q33399862-905798A7-C3F7-4650-8A71-F4752697AADEQ33844947-8867D38B-B206-4009-B628-FCE0B684470FQ34081877-649A5ACE-33CC-42DE-B90B-BE893585F80BQ34896439-65172BD4-2053-4E1F-9875-1E1806D51DFFQ35207886-A8D10B16-24F9-4923-B02D-1306FC3FFB21Q35475541-97073CEB-B843-4E65-97BA-5D6EB8B6EFE7Q35636615-714A1924-AFF0-489F-A38C-A0E2EA37B904Q35638299-14823FB2-2AA8-4069-A98A-8BEC69D2081BQ35645491-33919DEB-D218-45E9-97C1-63C66A27EEF3Q35760039-5505AFCC-56E8-47B7-A784-3D170AB14233Q35808002-6702F16D-9D9A-4AC2-BFD8-5726B3F25E0AQ36085007-57EC6F92-462D-4C7E-A952-C34A81F0CB3EQ36214720-6F080C2D-7D3E-4834-B25E-2B9AE44B036AQ36395509-AE1CDC01-E4CB-476D-98E2-B9F023494598Q36401901-F0C58C0D-A07A-4EB2-B620-EC1D4431E20DQ36691738-0CB014DF-F50A-4AE9-8440-FED4710BDB6BQ36708319-01637A7A-8395-4F48-9A62-16EAC474294DQ36733774-2E08FAAE-19E4-45D6-B6C9-2AAA580DCC8DQ36740473-81827741-9266-4A75-9C79-6B1C0611B8AEQ36958337-289E9725-FBDE-4131-8A12-027A4DB92841Q37000109-815FFB96-E24D-4E01-94FE-85AA5247F968Q37071611-DC919181-8DFA-4931-9818-742355B120A1Q37076880-C40D4D99-0751-44A2-BEA0-7542208B12FCQ37270787-EE523FC4-8089-43A6-BF65-4079889F5B03Q37280952-FB6A173D-7E67-4D35-8201-7C45CC547A9BQ37586832-9AFFE82F-23CC-4D2E-9798-8FDD8A75A05CQ37624583-B80D35ED-3A69-4077-B394-1CE589C8DE14Q37693939-589ACC90-CEA2-4605-8C09-A60E8FCF8B65Q37951648-BEDDF58F-7580-434B-B6E8-28D45F656736Q38236144-8B8C35D0-65F9-4BB3-AF52-ECFD66F3B217Q38610068-7EEEF209-0642-4582-ACA6-42459C149CCAQ38857820-321B1897-444C-4843-84F4-327BD9FE5555
P2860
Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Decrease of anti-cyclic citrul ...... ated with clinical improvement
@ast
Decrease of anti-cyclic citrul ...... ated with clinical improvement
@en
type
label
Decrease of anti-cyclic citrul ...... ated with clinical improvement
@ast
Decrease of anti-cyclic citrul ...... ated with clinical improvement
@en
prefLabel
Decrease of anti-cyclic citrul ...... ated with clinical improvement
@ast
Decrease of anti-cyclic citrul ...... ated with clinical improvement
@en
P2093
P2860
P356
P1476
Decrease of anti-cyclic citrul ...... ated with clinical improvement
@en
P2093
Alessandri C
Bombardieri M
Cinquini M
P2860
P304
P356
10.1136/ARD.2003.014647
P407
P577
2004-10-01T00:00:00Z